N@N

Market Maker Surveillance Report. STEM, RITT, ALTH, FTEK, OXBT, ANTH, Winning Stocks With Lowest Price Friction For Tuesday, J

July 17, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3947 companies with "abnormal" market making, 2987 companies with positive Friction Factors and 2390 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. StemCells Inc (NASDAQ:STEM), Rit Technologies Ltd (NASDAQ:RITT), Allos Therapeutics Inc (NASDAQ:ALTH), Fuel Tech Inc (NASDAQ:FTEK), Oxygen Biotherapeutics Inc (NASDAQ:OXBT), Anthera Pharmaceuticals Inc (NASDAQ:ANTH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  STEM    $0.990    113.79%   9,037,447    53.59%    7,816,108    46.35%    1,221,339    12,337  
  RITT    $0.800    27.31%    260,536      57.50%    187,515      41.39%    73,021       913     
  ALTH    $0.310    21.68%    1,329,334    57.31%    990,078      42.68%    339,256      10,944  
  FTEK    $0.830    18.16%    319,970      50.64%    295,990      46.85%    23,980       289     
  OXBT    $0.230    16.67%    80,807       60.42%    52,746       39.44%    28,061       1,220   
  ANTH    $0.220    16.54%    12,775,013   50.66%    12,434,777   49.31%    340,236      15,465  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows STEM with a dollar gain Tuesday of $0.99000 and a Friction Factor of 12,337 shares. That means that it only took 12,337 more shares of buying than selling to move STEM higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

StemCells Inc (NASDAQ:STEM) - StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of stem cell therapeutics and related technologies. It develops cell-based therapeutics for the central nervous system and liver. The companys lead product candidate, HuCNS-SC cells have completed a Phase I clinical trial for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis, a neurodegenerative disease that affects infants and young children. HuCNS-SC cells are also in Phase I clinical trial for the treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. In addition, it involves in preclinical development with its human liver engrafting cells (hLEC) to evaluate hLEC as a potential cellular therapy for a range of liver diseases. Further, the company is developing and commercializing applications of its technologies to enable stem cell-based research to academic and industrial laboratories. It markets a range of proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2B27, NDiff 2 and 27 supplements, HEScGRO, and ESGRO Complete proprietary media. StemCells, Inc. has exclusive rights to approximately 50 issued or allowed U.S. patents, and 200 granted or allowed non-U.S. patents. The company was founded in 1988 and is based in Palo Alto, California.

Rit Technologies Ltd (NASDAQ:RITT) - RiT Technologies Ltd. develops intelligent physical layer management solutions for the control, utilization, and maintenance of networks worldwide. The company offers structured cabling products, including SMART Cabling System, an end-to-end network infrastructure solution that provides connectivity solutions for copper and fiber; and CLASSix, a cabling product line, which supports data communication protocols, such as gigabit Ethernet. Its products include PatchView, an intelligent infrastructure management solution that offers real-time connectivity information to the data networks connectivity infrastructure; PatchView for the Enterprise software to identify infrastructure connections in real-time and network resources; and PVMax, a hardware platform for PatchView. In addition, the company offers PV4E network management software and a RiT private label version of a midspan power over Ethernet solution; SMARTen 10GB cabling solution; SiteWiz cable and asset management software solution; SitePro, a software solution for hand-held devices; and Paladin for environment and security management. Further, it provides PairView, an outside plant management and qualification system that enables telecos to identify, record, and test the connectivity routing of local loop pairs, and update their database; PairQ to transfer high bandwidth communication on plain regular old telephone lines for digital subscriber line services markets; PairView Pro, a local loop mass verification system to identify and map various digital services; NGPair for street cabinet migration and automatic MDF installation; and PairGuide, a single point of interface to the Carrier OSS. The company offers its solutions through distributors, strategic alliance partners, value-added resellers, system integrators, OEMs, and installers. It has strategic alliances with 3M, Brand-Rex, Belden/CDT, ADC, Furukawa, LS Cable, and Connectix. The company was founded in 1989 and is headquartered in Tel Aviv, Israel.

Allos Therapeutics Inc (NASDAQ:ALTH) - Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics. It is developing FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The company is also developing FOLOTYN as a single agent and in combination therapy regimens in various hematologic malignancies and solid tumor indications, including stage IV breast cancer and recurrent/metastatic head and neck cancer. It sells FOLOTYN to pharmaceutical wholesale distributors who then resell it to patients respective health care providers. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado.

Fuel Tech Inc (NASDAQ:FTEK) - Fuel Tech, Inc. provides engineering solutions for the optimization of combustion systems in utility and industrial applications worldwide. It offers boiler optimization, and air pollution reduction and control solutions. The company operates in two segments, Air Pollution Control Technologies and FUEL CHEM Technologies. The Air Pollution Control Technologies segment includes technologies that reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. These technologies comprise low- and ultra-low NOx burners, over-fire air systems, NOxOUT and HERT selective non-catalytic reduction systems, and selective catalytic reduction systems. The FUEL CHEM Technologies segment uses chemical processes in combination with CFD and CKM boiler modeling, for the control of slagging, fouling, corrosion, opacity, and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology. The company distributes its products through its direct sales force, licensees, and agents. Fuel Tech, Inc. was founded in 1987 and is headquartered in Warrenville, Illinois.

Oxygen Biotherapeutics Inc (NASDAQ:OXBT) - Oxygen Biotherapeutics, Inc. develops medical and cosmetic products that deliver oxygen to tissues in the body. It develops a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery for conditions, including but not limited to traumatic brain injury, decompression sickness, cosmetics, and topical wounds. The companys under development product include Vitavent, an oxygen exchange fluid for facilitating the treatment of lung conditions. In addition, it out-licensed its rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. Further, Oxygen Biotherapeutics offers Dermacyte line of oxygen-rich skin care products that promote the appearance of skin health and other desirable cosmetic benefits; and Wundecyte, a wound-healing gel. The company markets and sells Dermacyte line of products through www.buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales and exclusive distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics was founded in 1967 and is based in Durham, North Carolina.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) - Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net